This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Turner, A. K.
Right arrow Articles by Darsley, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Turner, A. K.
Right arrow Articles by Darsley, M. J.

 Previous Article  |  Next Article 

Infection and Immunity, February 2006, p. 1062-1071, Vol. 74, No. 2
0019-9567/06/$08.00+0     doi:10.1128/IAI.74.2.1062-1071.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Construction and Phase I Clinical Evaluation of the Safety and Immunogenicity of a Candidate Enterotoxigenic Escherichia coli Vaccine Strain Expressing Colonization Factor Antigen CFA/I

Arthur K. Turner,1,{dagger} Juliet C. Beavis,1 Jonathan C. Stephens,1,{ddagger} Judith Greenwood,1 Cornelia Gewert,1 Nicola Thomas,1 Alison Deary,1 Gabriella Casula,1 Alexandra Daley,2 Paul Kelly,2 Roger Randall,1 and Michael J. Darsley1*

Acambis, 100 Fulbourn Road, Cambridge CB1 9PT, United Kingdom,1 Institute of Cell and Molecular Science, Barts and the London School of Medicine, Turner Street, London E1 2AD, United Kingdom2

Received 8 August 2005/ Returned for modification 4 November 2005/ Accepted 15 November 2005

Oral delivery of toxin-negative derivatives of enterotoxigenic Escherichia coli (ETEC) that express colonization factor antigens (CFA) with deletions of the aroC, ompC, ompF, and toxin genes may be an effective approach to vaccination against ETEC-associated diarrhea. We describe the creation and characterization of an attenuated CFA/I-expressing ETEC vaccine candidate, ACAM2010, from a virulent isolate in which the heat-stable enterotoxin (ST) and CFA/I genes were closely linked and on the same virulence plasmid as the enteroaggregative E. coli heat-stable toxin (EAST1) gene. A new suicide vector (pJCB12) was constructed and used to delete the ST and EAST1 genes and to introduce defined deletion mutations into the aroC, ompC, and ompF chromosomal genes. A phase I trial, consisting of an open-label dose escalation phase in 18 adult outpatient volunteers followed by a placebo-controlled double-blind phase in an additional 31 volunteers, was conducted. The vaccine was administered in two formulations, fresh culture and frozen suspension. These were both well tolerated, with no evidence of significant adverse events related to vaccination. Immunoglobulin A (IgA) and IgG antibody-secreting cells specific for CFA/I were assayed by ELISPOT. Positive responses (greater than twofold increase) were seen in 27 of 37 (73%) subjects who received the highest dose level of vaccine (nominally 5 x 109 CFU). Twenty-nine of these volunteers were secreting culturable vaccine organisms at day 3 following vaccination; five were still positive on day 7, with a single isolation on day 13. This live attenuated bacterial vaccine is safe and immunogenic in healthy adult volunteers.

* Corresponding author. Present address: Cambridge Biostability Limited (CBL), NIAB, Huntingdon Road, Cambridge CB3 0LE, United Kingdom. Phone: 44 (0) 1223 279002. Fax: 44 (0) 1223 279089. E-mail: mike.darsley{at}biostability.com.

Editor: A. D. O'Brien

{dagger} Present address: The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, United Kingdom.

{ddagger} Present address: University of Cambridge, Division of Transfusion Medicine, Department of Haematology, Long Road, Cambridge CB2 2PT, United Kingdom.

Infection and Immunity, February 2006, p. 1062-1071, Vol. 74, No. 2
0019-9567/06/$08.00+0     doi:10.1128/IAI.74.2.1062-1071.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Daley, A., Randall, R., Darsley, M., Choudhry, N., Thomas, N., Sanderson, I. R, Croft, N. M, Kelly, P. (2007). Genetically modified enterotoxigenic Escherichia coli vaccines induce mucosal immune responses without inflammation. Gut 56: 1550-1556 [Abstract] [Full Text]  
  • Qadri, F., Ahmed, T., Ahmed, F., Bhuiyan, M. S., Mostofa, M. G., Cassels, F. J., Helander, A., Svennerholm, A.-M. (2007). Mucosal and Systemic Immune Responses in Patients with Diarrhea Due to CS6-Expressing Enterotoxigenic Escherichia coli. Infect. Immun. 75: 2269-2274 [Abstract] [Full Text]  
  • Turner, A. K., Nair, S., Wain, J. (2006). The acquisition of full fluoroquinolone resistance in Salmonella Typhi by accumulation of point mutations in the topoisomerase targets. J Antimicrob Chemother 58: 733-740 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»